期刊
ONKOLOGIE
卷 31, 期 11, 页码 629-633出版社
KARGER
DOI: 10.1159/000160599
关键词
Acute myeloid leukemia; Valproic acid; All-trans retinoic acid; Myelodysplastic syndrome; HDAC inhibitors
类别
资金
- Deutsche Forschungsgemeinschaft [Ma 2057/2-4]
- Deutsche Jose Carreras Leukamie-Stiftung (DJCLS) [R05/11]
Currently, no standard treatment is available for elderly patients with de novo/secondary acute myeloid leukemia (AML) who are not eligible for intensive chemotherapy. New, less aggressive therapies are therefore needed. His tone deacetylase inhibitors (HDACi) are known to reduce proliferation and induce differentiation in hematological malignancies. With all-trans retinoic acid (ATRA) these effects have been reported to be even enhanced. Valproic acid (VPA) is an HDACi and has been known as anti-epileptic agent for many years. We treated 21 patients with de novo/secondary AML and 1 patient with myelodysplastic syndrome with ATRA (45 mg/m(2)/day in 2 doses, 14 days, q29 days) and VPA (150 mg/day 1 week, then 300 mg/day, continuously). Treatment was tolerated well with moderate side effects. 4 patients revealed hematological improvement and another 4 patients experienced a reduction in transfusion dependency. The overall response rate was 27%. Our study is presented together with an overview of the literature on the topic.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据